乙酰半胱氨酸联合布地奈德福莫特罗治疗COPD稳定期的临床效果分析  

Clinical effects of acetylcysteine combined with budesonide and formoterol in the treatment of COPD at stable stage

作　　者：李雪艳 LI Xue-yan(Department of Internal Medicine,Liaozhong Changjiang Hospital,Shenyang 110200,China)

机构地区：[1]沈阳市辽中长江医院内科,110200

出　　处：《中国实用医药》2022年第11期5-8,共4页China Practical Medicine

摘　　要：目的探讨对慢性阻塞性肺疾病(COPD)稳定期患者采用乙酰半胱氨酸联合布地奈德福莫特罗进行治疗的临床效果。方法68例COPD稳定期患者,随机分为参照组和试验组,每组34例。对照组采用布地奈德福莫特罗治疗,试验组采用乙酰半胱氨酸联合布地奈德福莫特罗治疗。比较两组患者治疗效果及治疗前后炎性因子[C反应蛋白(CRP)、白细胞介素-6(IL-6)、降钙素原(PCT)]、肺功能[第1秒用力呼气容积(FEV1)、第1秒用力呼气容积占用力肺活量的百分比(FEV1/FVC)]水平。结果试验组治疗总有效率为94.12%,高于参照组的73.53%,差异具有统计学意义(P<0.05)。治疗前,试验组患者CRP、IL-6、PCT水平分别为(18.79±4.06)mg/L、(15.52±3.81)ng/L、(4.35±1.39)μg/L,与参照组的(18.72±5.01)mg/L、(15.08±3.83)ng/L、(4.37±1.41)μg/L比较,差异无统计学意义(P>0.05)。治疗后,试验组患者CRP、IL-6、PCT水平分别为(6.29±2.89)mg/L、(9.16±1.03)ng/L、(1.19±0.25)μg/L,均低于参照组的(13.06±3.29)mg/L、(11.29±2.15)ng/L、(2.92±0.53)μg/L,差异具有统计学意义(P<0.05)。治疗前,试验组患者FEV1、FEV1/FVC分别为(1.33±0.23)L、(51.77±2.75)%,与参照组的(1.36±0.25)L、(51.79±2.88)%比较,差异无统计学意义(P>0.05)。治疗后,试验组患者FEV1、FEV1/FVC分别为(1.73±0.25)L、(63.57±2.49)%,高于参照组的(1.59±0.21)L、(60.23±2.71)%,差异具有统计学意义(P<0.05)。结论乙酰半胱氨酸联合布地奈德福莫特罗联合治疗COPD稳定期患者可显著增强疗效,降低炎性因子水平,提升肺功能,值得临床推广应用。Objective To discuss the clinical effect of acetylcysteine combined with budesonide and formoterol in the treatment of chronic obstructive pulmonary disease(COPD) at stable stage. Methods A total of 68 patients with stable COPD were randomly divided into reference group and experimental group, with 34 cases in each group. The reference group was treated with budesonide and formoterol, and the experimental group was treated with acetylcysteine and budesonide and formoterol. Both groups were compared in terms of therapeutic effect and the levels of inflammatory factors [C-reactive protein(CRP), interleukin-6(IL-6),procalcitonin(PCT)], and pulmonary function [forced expiratory volume in the 1st second(FEV1), FEV1/forced vital capacity(FEV1/FVC)] before and after treatment. Results The total effective rate of treatment in the experimental group was 94.12%, which was higher than 73.53% in the reference group, and the difference was statistically significant(P<0.05). Before treatment, the levels of CRP, IL-6, and PCT in the experimental group were(18.79±4.06) mg/L,(15.52±3.81) ng/L, and(4.35±1.39) μg/L, which were not statistically significant compared with(18.72±5.01) mg/L,(15.08±3.83) ng/L, and(4.37±1.41) μg/L in the reference group(P>0.05).After treatment, the levels of CRP, IL-6 and PCT in the experimental group were(6.29±2.89) mg/L,(9.16±1.03) ng/L, and(1.19±0.25) μg/L, which were lower than(13.06±3.29) mg/L,(11.29±2.15) ng/L, and(2.92±0.53) μg/L in the reference group, and the difference was statistically significant(P<0.05). Before treatment, the FEV1 and FEV1/FVC in the experimental group were(1.33±0.23) L and(51.77±2.75)%, which were not statistically significant compared with(1.36±0.25) L and(51.79±2.88)% in the reference group(P>0.05).After treatment, the FEV1 and FEV1/FVC in the experimental group were(1.73±0.25) L and(63.57±2.49)%,which were higher than(1.59±0.21) L and(60.23±2.71)% in the reference group, and the difference was statistically significant(P<0.05). Conclusion The comb

关 键 词：慢性阻塞性肺疾病稳定期 乙酰半胱氨酸 布地奈德福莫特罗 疗效 炎性因子 肺功能 

分 类 号：R563.9[医药卫生—呼吸系统]